Substance
ID:4500
Names and Identifiers
Brand Name
LinamiphenMeritalNomifenison
Synonyms
(+-)-nomifensinNomifensineNomifensine hydrogen maleateNomifensine maleate(+-)-nomifensine2-Methyl-4-phenyl-1,2,3,4-tetrahydro-8-isoquinolinamine8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisoquinoline8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolineNomifensina [inn-spanish](+)-nomiphensine8-Amino-1,2,3,4-tetrahydro-2-methyl-4-phenylisochinolinNomifensinum [inn-latin]Nomifensin(+)-nomifensine(R)-1,2,3,4-Tetrahydro-2-methyl-4-phenyl-8-isoquinolinamine
IUPAC Traditional name
nomifensine
IUPAC name
2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine
Properties
No Data Available
Click here to submit data
Molecule Details
Drug Groups
withdrawn
Description
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.
Pharmacology
Nomifensine is a dopamine reuptake inhibitor test-marketed in the United States by Hoechst AG (now Novartis) that increases the amount of synaptic dopamine available to receptors by blocking dopamine's re-uptake transporter. Nomifensine is now mainly used in scientific research, particularly in studies involving dopamine release in response to addiction.
Toxicity
A likely cause of nomifensine toxicity is the aromatic amine group, as compounds containing this chemical substructure are notorious for producing toxic metabolites.
Affected Organisms
Humans and other mammals
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data